A Study of Enlicitide Chloride (MK-0616 Oral PCSK9 Inhibitor) in Participants With Moderate Renal Impairment (MK-0616-007)

NCT05070390 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

18

Enrollment

INDUSTRY

Sponsor class

Conditions

Moderate Renal Impairment

Interventions

DRUG: Enlicitide Chloride

Sponsor

Merck Sharp & Dohme LLC